B. I. Eriksson, L. C. Borris, O. E. Dahl, S. Haas, M. V. Huisman, A. K. Kakkar, E. Muehlhofer, C. Dierig, F. Misselwitz, P. Kälebo: A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. In: Circulation, Band 114, Nummer 22, November 2006, S. 2374–2381, doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766. circ.ahajournals.org / Volltext (PDF; 508 kB)
G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. In: Circulation. Band 116, Nummer 2, Juli 2007, S. 180–187, doi:10.1161/CIRCULATIONAHA.106.668020. PMID 17576867. circ.ahajournals.org / Volltext (PDF; 453 kB)
K. Takács-Novák, M. Urac, P. Horváth, G. Völgyi, B. D. Anderson, A. Avdeef: Equilibrium solubility measurement of compounds with low dissolution rate by Higuchi’s Facilitated Dissolution Method. A validation study. In: Eur. J. Pharm. Sci., 106, 2017, S. 133–144, doi:10.1016/j.ejps.2017.05.064.
J. Stampfuss, D. Kubitza, M. Becka, W. Mueck: The effect of food on the absorption and pharmacokinetics of rivaroxaban. In: Int J Clin Pharmacol Ther. 51(7), Jul 2013, S. 549–561. doi:10.5414/CP201812. PMID 23458226
M. R. Lassen, W. Ageno, L. C. Borris, J. R. Lieberman, N. Rosencher, T. J. Bandel, F. Misselwitz, A. G. Turpie: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. In: The New England Journal of Medicine. Band 358, Nummer 26, Juni 2008, S. 2776–2786, doi:10.1056/NEJMoa076016. PMID 18579812.
B. I. Eriksson, L. C. Borris, R. J. Friedman, S. Haas, M. V. Huisman, A. K. Kakkar, T. J. Bandel, H. Beckmann, E. Muehlhofer, F. Misselwitz, W. Geerts: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. In: The New England Journal of Medicine, Band 358, Nummer 26, Juni 2008, S. 2765–2775, doi:10.1056/NEJMoa0800374. PMID 18579811.
B. I. Eriksson, L. C. Borris, O. E. Dahl, S. Haas, M. V. Huisman, A. K. Kakkar, E. Muehlhofer, C. Dierig, F. Misselwitz, P. Kälebo: A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. In: Circulation, Band 114, Nummer 22, November 2006, S. 2374–2381, doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766. circ.ahajournals.org / Volltext (PDF; 508 kB)
G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. In: Circulation. Band 116, Nummer 2, Juli 2007, S. 180–187, doi:10.1161/CIRCULATIONAHA.106.668020. PMID 17576867. circ.ahajournals.org / Volltext (PDF; 453 kB)
Alexander T. Cohen, Theodore E. Spiro u. a.: Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. In: New England Journal of Medicine. 368, 2013, S. 513, doi:10.1056/NEJMoa1111096 (freier Volltext).
Jessica L. Mega, Eugene Braunwald u. a.: Rivaroxaban in Patients with a Recent Acute Coronary Syndrome. In: New England Journal of Medicine. 366, 2012, S. 9, doi:10.1056/NEJMoa1112277 (freier Volltext).
Warren H. Capell, Marc P. Bonaca, Mark R. Nehler, Edmond Chen, John M. Kittelson: Rationale and design for the Vascular Outcomes study of ASA along with rivaroxaban in endovascular or surgical limb revascularization for peripheral artery disease (VOYAGER PAD). In: American Heart Journal. Band199, Mai 2018, S.83–91, doi:10.1016/j.ahj.2018.01.011.
Marc P. Bonaca, Rupert M. Bauersachs, Sonia S. Anand, E. Sebastian Debus, Mark R. Nehler: Rivaroxaban in Peripheral Artery Disease after Revascularization. In: New England Journal of Medicine. Band382, Nr.21, 21. Mai 2020, S.1994–2004, doi:10.1056/NEJMoa2000052.
E. S. Eerenberg, P. W. Kamphuisen, M. K. Sijpkens, J. C. Meijers, H. R. Buller, M. Levi: Reversal of Rivaroxaban and Dabigatran by Prothrombin Complex Concentrate: A Randomized, Placebo-Controlled, Crossover Study in Healthy Subjects. In: Circulation, 2011, 124, S. 1573–1579, doi:10.1161/CIRCULATIONAHA.111.029017.
S. T. Lo et al.: Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease. In: Journal of feline medicine and surgery. Band 24, Nummer 4, April 2022, S. 277–283, doi:10.1177/1098612X211013736, PMID 33966532, PMC 8830184 (freier Volltext).
Julien Guillaumin: Feline Aortic Thromboembolism: Recent advances and future prospects. In: Journal of Feline Medicine and Surgery. 2024, Band 26, Nummer 6 doi:10.1177/1098612X241257878.
europa.eu
ema.europa.eu
Xarelto. Summary of the European Public Assessment Report (EPAR), EMA (englisch).
Prescriber Update, Vol 40, No. 1, Medsafe, March 2019 medsafe.govt.nz
nih.gov
ncbi.nlm.nih.gov
J. Stampfuss, D. Kubitza, M. Becka, W. Mueck: The effect of food on the absorption and pharmacokinetics of rivaroxaban. In: Int J Clin Pharmacol Ther. 51(7), Jul 2013, S. 549–561. doi:10.5414/CP201812. PMID 23458226
M. Çelebier, T. Reçber, E. Koçak, S. Altınöz, S. Kır: Determination of Rivaroxaban in Human Plasma by Solid-Phase Extraction-High Performance Liquid Chromatography. In: J Chromatogr Sci. 54(2), Feb 2016, S. 216–220. PMID 26351327
J. Kuhn, T. Gripp, T. Flieder, M. Dittrich, D. Hendig, J. Busse, C. Knabbe, I. Birschmann: UPLC-MRM Mass Spectrometry Method for Measurement of the Coagulation Inhibitors Dabigatran and Rivaroxaban in Human Plasma and Its Comparison with Functional Assays. In: PLoS One, 10(12), 23. Dez 2015, S. e0145478. PMID 26699714
E. Perzborn, D. Kubitza, F. Misselwitz: Rivaroxaban. A novel, oral, direct factor Xa inhibitor in clinical development for the prevention and treatment of thromboembolic disorders. In: Hämostaseologie. Band 27, Nummer 4, September 2007, S. 282–289. PMID 17938768.
M. R. Lassen, W. Ageno, L. C. Borris, J. R. Lieberman, N. Rosencher, T. J. Bandel, F. Misselwitz, A. G. Turpie: Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. In: The New England Journal of Medicine. Band 358, Nummer 26, Juni 2008, S. 2776–2786, doi:10.1056/NEJMoa076016. PMID 18579812.
B. I. Eriksson, L. C. Borris, R. J. Friedman, S. Haas, M. V. Huisman, A. K. Kakkar, T. J. Bandel, H. Beckmann, E. Muehlhofer, F. Misselwitz, W. Geerts: Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. In: The New England Journal of Medicine, Band 358, Nummer 26, Juni 2008, S. 2765–2775, doi:10.1056/NEJMoa0800374. PMID 18579811.
B. I. Eriksson, L. C. Borris, O. E. Dahl, S. Haas, M. V. Huisman, A. K. Kakkar, E. Muehlhofer, C. Dierig, F. Misselwitz, P. Kälebo: A once-daily, oral, direct Factor Xa inhibitor, rivaroxaban (BAY 59-7939), for thromboprophylaxis after total hip replacement. In: Circulation, Band 114, Nummer 22, November 2006, S. 2374–2381, doi:10.1161/CIRCULATIONAHA.106.642074. PMID 17116766. circ.ahajournals.org / Volltext (PDF; 508 kB)
G. Agnelli, A. Gallus, S. Z. Goldhaber, S. Haas, M. V. Huisman, R. D. Hull, A. K. Kakkar, F. Misselwitz, S. Schellong: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59-7939): the ODIXa-DVT (Oral Direct Factor Xa Inhibitor BAY 59-7939 in Patients With Acute Symptomatic Deep-Vein Thrombosis) study. In: Circulation. Band 116, Nummer 2, Juli 2007, S. 180–187, doi:10.1161/CIRCULATIONAHA.106.668020. PMID 17576867. circ.ahajournals.org / Volltext (PDF; 453 kB)
D. M. Siegal, J. T. Curnutte, S. J. Connolly, G. Lu, P. B. Conley, B. L. Wiens, V. S. Mathur, J. Castillo, M. D. Bronson, J. M. Leeds, F. A. Mar, A. Gold, M. A. Crowther: Andexanet Alfa for the Reversal of Factor Xa Inhibitor Activity. In: N Engl J Med. 373, 2015, S. 2413–2424. PMID 26559317.
S. T. Lo et al.: Dual therapy with clopidogrel and rivaroxaban in cats with thromboembolic disease. In: Journal of feline medicine and surgery. Band 24, Nummer 4, April 2022, S. 277–283, doi:10.1177/1098612X211013736, PMID 33966532, PMC 8830184 (freier Volltext).
